|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K 16/32 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| G01N 33/574 | (2006.01) |
| (11) | Number of the document | 2993187 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15181115.5 |
| Date of filing the European patent application | 2006-12-29 | |
| (97) | Date of publication of the European application | 2016-03-09 |
| (45) | Date of publication and mention of the grant of the patent | 2019-05-22 |
| (46) | Date of publication of the claims translation | 2019-09-10 |
| (30) | Number | Date | Country code |
| 755103 P | 2005-12-30 | US |
| (72) |
ROTHE, Mike, DE
TREDER, Martin, DE
HARTMANN, Susanne, DE
FREEMAN, Dan, US
RADINSKY, Bob, US
BORGES, Eric, AT
|
| (73) |
Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, California 91320-1799,
US
Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 München, DE |
| (74) |
Genė Ona SRUOGIENĖ,
UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius,
LT
|
| (54) | Antikūnai, nukreipti į HER-3, ir jų panaudojimas |
| ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2024-11-25 | 19 | 347.00 EUR |
| 2025-12-29 |